Xspray gets CRL over third-party production issues; Oxford Biomedica buys site from Resilience subsidiarynews2025-10-09T13:01:01+00:00October 9th, 2025|Endpoints News|
Akero CEO is named chair of Expedition, which raised $165M for COPD drug from Chinanews2025-10-09T11:36:15+00:00October 9th, 2025|Endpoints News|
Finnish researchers report success in mid-stage study of heart disease gene therapynews2025-10-09T10:33:04+00:00October 9th, 2025|Endpoints News|
Ferring to downsize by up to 500 staffers in move towards new ‘enterprise model’news2025-10-09T10:30:00+00:00October 9th, 2025|Endpoints News|
Updated: Novo Nordisk to buy MASH player Akero for $4.7B upfrontnews2025-10-09T10:23:59+00:00October 9th, 2025|Endpoints News|
How LB Pharma landed the first big US biotech IPO since Februarynews2025-10-09T08:14:36+00:00October 9th, 2025|Endpoints News|
ARPA-H awards several biotechs funding to make in vivo therapiesnews2025-10-08T19:15:18+00:00October 8th, 2025|Endpoints News|
CBER chief Prasad hires ARPA-H doctor as one of two new acting deputiesnews2025-10-08T18:40:53+00:00October 8th, 2025|Endpoints News|
Q&A: Scientists behind Baby KJ’s custom CRISPR drug are planning to help more children news2025-10-08T18:29:20+00:00October 8th, 2025|Endpoints News|
Colorado drug board sets first state pricing limit for Amgen’s Enbrel in 2027news2025-10-08T17:41:32+00:00October 8th, 2025|Endpoints News|
